

AMCoR

Asahikawa Medical University Repository <http://amcor.asahikawa-med.ac.jp/>

Journal of gastroenterology and hepatology (2017.3) :1-25.

Repeated water avoidance stress induces visceral hypersensitivity; role of IL-1, IL-6 and peripheral corticotropin-releasing factor

Tsukasa Nozu, Saori Miyagishi, Rintaro Nozu, Kaoru Takakusaki, Toshikatsu Okumura

1 **Repeated water avoidance stress induces visceral hypersensitivity; role of**
2 **interleukin-1, interleukin-6 and peripheral corticotropin-releasing factor**

3

4 Tsukasa Nozu ¹, Saori Miyagishi ², Rintaro Nozu ¹, Kaoru Takakusaki ³, Toshikatsu
5 Okumura ²

6

7 ¹ Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-
8 1-1 Midorigaoka-Higashi, Asahikawa, Hokkaido, 078-8510, Japan

9 ² Division of Gastroenterology and Hematology/Oncology, Department of Medicine,
10 Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, Hokkaido,
11 078-8510, Japan

12 ³ Research Center for Brain Function and Medical Engineering, Asahikawa Medical
13 University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, Hokkaido, 078-8510, Japan

14

15 Address for corresponding:

16 Tsukasa Nozu, MD, PhD, FACP, FJSIM

17 Department of Regional Medicine and Education, Asahikawa Medical University, 2-1-
18 1-1 Midorigaoka-Higashi, Asahikawa, Hokkaido, 078-8510, Japan

19 Ph; +81-166-68-2844

20 Fax; +81-166-68-2846

21 e-mail; tnozu@sea.plala.or.jp

22

23 Disclosure statement

24 This work was partially supported by Japan Society for the Promotion of Science

25 KAKENHI, Grant-in-Aid for Scientific Research (C) [26460287 (TN) and 26460955

26 (TO)] and Scientific Research on Innovative Areas [26120012 (KT)].

27 **Background and Aim:** Repeated water avoidance stress (WAS) induces visceral
28 hypersensitivity. Additionally, it is also known to activate corticotropin-releasing factor
29 (CRF), mast cells and pro-inflammatory cytokines systems, but their precise roles on
30 visceral sensation have not been determined definitely. The aim of the study was to
31 explore this issue.

32 **Methods:** Abdominal muscle contractions induced by colonic balloon distention, i.e.
33 visceromotor response (VMR) was detected electrophysiologically in conscious rats.
34 WAS or sham stress as control for 1 hr daily was loaded and the threshold of VMR was
35 determined before and at 24 hr after the stress.

36 **Results:** Repeated WAS for 3 consecutive days reduced the threshold of VMR, but
37 sham stress did not induce any change. Astressin, a CRF receptor antagonist (50 µg/kg)
38 intraperitoneally (ip) at 10 min prior to each WAS session prevented the visceral
39 allodynia, but the antagonist (200 µg/kg) ip at 30 min and 15 hr before measurement of
40 the threshold after completing 3-day stress session did not modify the response.
41 Ketotifen, a mast cell stabilizer (3 mg/kg), anakinra, an interleukin (IL)-1 receptor
42 antagonist (20 mg/kg) or IL-6 antibody (16.6 µg/kg) ip for 2 times before the
43 measurement abolished the response.

44 **Conclusions:** Repeated WAS for 3 consecutive days induced visceral allodynia which
45 was mediated through mast cells, IL-1 and IL-6 pathways. Inhibition of peripheral CRF
46 signaling prevented but did not reverse this response, suggesting that peripheral CRF
47 may be an essential trigger but may not contribute to the maintenance of repeated WAS-
48 induced visceral allodynia.

49

50 **Key words**

51 Repeated water avoidance stress; Visceral allodynia; Corticotropin-releasing factor;

52 Cytokine; Mast cell

53 **Introduction**

54 Irritable bowel syndrome (IBS) is one of the functional gastrointestinal (GI) disorders
55 characterized by the presence of recurrent abdominal pain with altered bowel habits
56 without any organic cause.¹ Stress induces onset and/or exaggeration of GI symptoms in
57 the majority of IBS patients.² The pathophysiology has not been completely defined but
58 disturbed gut motility and altered visceral sensory function play an important role at
59 least in part.³ Since stress alters GI motility and visceral sensation through central and
60 peripheral corticotropin-releasing factor (CRF), CRF-mediated GI responses are thought
61 to be involved in IBS pathophysiology.^{3, 4}

62 The actions of CRF are mediated through the activation of two receptors, CRF
63 receptor type 1 (CRF₁) and type 2 (CRF₂),⁵ and activation of each CRF receptor
64 induces distinct responses in GI tract, i.e. stimulation of colonic motility and inducing
65 visceral hypersensitivity to colorectal distension (CRD) by CRF₁, and delayed gastric
66 emptying by CRF₂ exclusively.^{3, 4, 6}

67 Water avoidance stress (WAS) is a conventional psychological stress protocol,
68 and several studies reported that repeated WAS induced visceral hyperalgesia in
69 rodents.⁷⁻¹⁰ Since accumulation of continuous life stress (chronic stress) often causes the
70 exacerbation of symptoms in IBS,¹¹ chronic repeated WAS is thought to be an
71 appropriate animal stress model of IBS.¹² Although WAS is well known to activate CRF
72 signaling¹³ and increase the expression of pro-inflammatory cytokines in GI tract,^{7, 8}
73 but their roles on visceral hypersensitivity have not been determined definitely and
74 directly.

75 We have very recently shown that lipopolysaccharide (LPS)-induced visceral
76 allodynia was mediated through peripheral CRF, interleukin (IL)-1 and IL-6 in rats.¹⁴
77 Incidentally, several investigators reported that circulatory LPS and pro-inflammatory
78 cytokines were increased in IBS^{15, 16} and suggested that LPS-cytokines system may be
79 involved in the visceral hypersensitivity observed in IBS.¹⁷ In this context, LPS-induced
80 visceral hypersensitivity is thought to simulate the pathophysiology of IBS. Then, we
81 hypothesized that repeated WAS-induced visceral hypersensitivity is mediated through
82 common pathways to LPS, i.e. peripheral CRF, IL-1 and IL-6.

83 In the present study, we established the rat model of visceral hypersensitivity
84 induced by repeated WAS, and the roles of peripheral CRF signaling, IL-1 and IL-6
85 were determined in this model. Additionally, since LPS or WAS was also reported to
86 activate mast cells,¹⁸ the role was also explored.

87

88 **Materials and Methods**

89 **Animals.** Adult male Sprague-Dawley rats (Charles River Laboratory, Atsugi, Japan)
90 weighing about 300 g were housed grouply (3–4 rats/cage) under controlled conditions
91 of illumination (12 hr light/dark cycle starting at 7 a.m.) and temperature at 23–25 °C
92 with food (Solid rat chow, Oriental Yeast, Tokyo, Japan) and water available ad libitum.

93

94 **Chemicals.** Astressin (Sigma-Aldrich, St. Louis, MO, USA), a non-selective CRF₁ and
95 CRF₂ receptor antagonist was dissolved in double-distilled water. Anakinra (Swedish
96 Orphan Biovitrum, Stockholm, Sweden), an IL-1 receptor antagonist and ketotifen
97 (Sigma-Aldrich), a connective tissue mast cell stabilizer were dissolved in normal

98 saline. Goat anti-rat IL-6 neutralizing antibody and normal goat IgG (R&D Systems,
99 Minneapolis, MN, USA) were dissolved in sterile phosphate buffered saline. The doses
100 of the chemicals were determined according to the previous reports.^{14, 19} The volume of
101 injection was 0.2 mL/rat.

102

103 ***Measurement of visceral sensation.*** Visceral sensation was assessed by abdominal
104 muscle contractions induced by colonic distention (visceromotor response; VMR) using
105 electromyogram (EMG) in conscious rats, which was validated as quantitative measure
106 of visceral nociception.²⁰

107

108 ***Implantation of electrodes and placement of colonic distention balloon.*** Under brief
109 ether anesthesia, a small skin incision about 5 mm in length was made in non-fasted
110 rats, and electrodes (Teflon coated stainless steel, 0.05 mm diameter, MT Giken, Tokyo,
111 Japan) for EMG were inserted approximately 2 mm into left side external oblique
112 musculature through the incision. They were fixed to musculature and the incised skin
113 was closed by cyanoacrylate instant adhesive (Aron Alpha, TOAGOSEI, Tokyo, Japan).
114 The electrode leads were externalized directly through this closed incision without
115 subcutaneous tunnel and threaded through a urethane tube. Distension balloon (6-Fr
116 disposable silicon balloon-urethral catheter, JU-SB0601, Terumo Corporation, Tokyo,
117 Japan) was inserted intra-anally with the distal end positioned 2 cm proximal to the
118 anus. The volume and length of maximally inflated balloon was 1.5 mL and 1.2 cm.

119

120 ***Colonic distention and measuring abdominal muscle contractions.*** After completing
121 the surgery for the electrodes implantation and balloon placement, the rats were placed
122 in Bollmann cages and allowed to recover from the anesthesia, and acclimated to the
123 experimental condition for 30 min before testing. (The animals were trained to the
124 experimental conditions by placing them singly in Bollmann cages for 1 hr before the
125 day of experiment.) Later electrode leads were connected to an EMG amplifier, and
126 EMG signals were amplified, filtered (3000 Hz), digitized by a PowerLab system (AD
127 Instruments, Colorado Springs, CO, USA) and recorded using computer software
128 (LabChart 7, AD Instruments). Colonic distension was performed at 30 min after the
129 surgery according to a previous publication,¹⁴ namely, ascending method of limits
130 phasic distension was applied in increments of 0.1 mL for 5 sec by inflating the balloon
131 by water using a syringe manually until significant abdominal muscle contractions, i.e.
132 VMR, were detected. The threshold of VMR was defined as the distended balloon
133 volume (mL) inducing VMR (Fig.1A). Tang et al.²¹ previously demonstrated that the
134 pain threshold induced by CRD assessed by the observation of abdominal withdrawal
135 reflex using the balloon quite similar to ours could be determined as distended balloon
136 volume in rats and also showed that intracolonic pressure was linearly associated with
137 intraballoon volume. The threshold was assessed two times (2 min interval) and the
138 mean of the threshold was calculated as the data of the animals.

139

140 ***Stress protocol.*** Exposure to WAS was performed as described previously.²² Rats were
141 placed individually on a plastic platform (height, 8 cm; length, 6 cm; width, 6 cm)
142 positioned in the middle of a plastic cage filled with water up to 7 cm of the height of
143 the platform. To avoid contact with water, rats stood on a platform during the entire

144 stress period. Control animals were also put on the same plastic platform in a plastic
145 cage but not filled with water (sham stress).

146

147 ***Experimental procedures.*** The non-fasted rats were submitted to colonic balloon
148 distention and the basal threshold of VMR was measured. Then the electrodes and
149 distention balloon were removed, and either WAS or sham stress (controls) for 1 hr was
150 applied. First, in order to establish the rat model of visceral hypersensitivity, we
151 determined the time course effect of repeated WAS from single session (Fig.1B). Each
152 group of animals (n = 6–9) was loaded by different times of daily 1-hr stress session,
153 and the experiment continued until detecting significant visceral allodynia after repeated
154 WAS. After completing each stress session, the animals were returned to their group
155 housing cages. Stress sessions were performed at 8–12 a.m. After 24 hr from the last
156 stress session, the animals underwent surgery for the electrodes implantation and
157 balloon placement, and put in the Bollmann cages again. After 30 min, the threshold
158 was determined.

159 Next, the mechanisms of repeated WAS-induced visceral hypersensitivity were
160 explored using this established model. The effect of astressin, ketotifen, anakinra and
161 IL-6 antibody were tested. These drugs were administered at 30 min and 15 hr before
162 colonic distention performed after completing repeated WAS or sham stress session
163 through intraperitoneal (ip) route (Fig.1C). In another series of experiment, astressin
164 was also administered at 10 min before each stress session, repeatedly (Fig.1D).

165

166 **Statistical analysis.** Data were expressed as means \pm SE. Multiple comparison was
167 performed by two-way ANOVA followed by Fisher's Least-Significant-Difference Test.
168 Comparison between two groups was performed using the Student's t or paired t test.
169 SYSTAT 13 software (Systat Software, Chicago, IL, USA) was used throughout the
170 study.

171

172 **Ethical considerations.** Approval by the Research and Development and Animal Care
173 Committees at the Asahikawa Medical University (#15132, approved on April 1, 2015)
174 was obtained for all studies.

175

176 **Results**

177 **Repeated daily WAS for 3 consecutive days induced visceral allodynia.** Single and 2-
178 day WAS session did not change the threshold of VMR at 24 hr after the last WAS
179 (Fig.2A). On the other hand, WAS for 3 consecutive days significantly reduced the
180 threshold (mL) from 0.53 ± 0.020 to 0.36 ± 0.031 ($p < 0.05$). Sham stress did not alter
181 it. Moreover, the % change threshold, i.e. the value of the threshold after stress divided
182 by the one of the basal threshold, multiplied by 100 was significantly reduced in 3-day
183 WAS group as compared with sham stress one (67.2 ± 5.8 for WAS vs. 97.8 ± 5.4 for
184 sham stress, $p < 0.05$), but it was not changed in single or 2-day WAS group (Fig.2B).
185 Since 3-day WAS was definitely demonstrated to induce visceral allodynia as described
186 above, the % change threshold was presented in the following experiments in order to
187 assess the effect of drugs on this response.

188

189 ***CRF receptor antagonist, astressin prevented but did not reverse repeated WAS-***
190 ***induced visceral allodynia.*** Ip repeated injections of astressin at 50 µg/kg before the
191 each stress session prevented the allodynia without altering the threshold in sham stress
192 group (effect of WAS: $F = 6.0$, $p < 0.05$, effect of astressin: $F = 11.8$, $p < 0.05$,
193 interaction of WAS and astressin: $F = 11.1$, $p < 0.05$, 96.2 ± 7.0 for vehicle + sham vs.
194 64.8 ± 4.9 for vehicle + WAS, $p < 0.05$, 101.7 ± 3.7 for astressin + WAS vs. vehicle +
195 WAS, $p < 0.05$, Fig.3A).

196 On the other hand, ip astressin at 200 µg/kg twice before measuring the
197 threshold after completing 3-day stress session neither modified the response induced
198 by repeated WAS nor the threshold in sham-stressed rats (effect of WAS: $F = 40.7$, $p <$
199 0.05 , effect of astressin: $F = 0.11$, $p > 0.05$, interaction of WAS and astressin: $F = 0.22$,
200 $p > 0.05$, Fig.3B). This dose of antagonist was known to block CRD- or LPS-induced
201 visceral hypersensitivity in rats.^{14, 23}

202

203 ***Mast cell stabilizer, ketotifen attenuated repeated WAS-induced visceral allodynia.***
204 Ketotifen at 3 mg/kg twice before measuring the threshold did not alter the threshold in
205 sham-stressed rats but reversed the WAS-induced response (effect of WAS: $F = 7.0$, $p <$
206 0.05 , effect of ketotifen: $F = 11.2$, $p < 0.05$, interaction of WAS and ketotifen: $F = 4.5$, p
207 < 0.05 , 94.1 ± 4.0 for sham + vehicle vs. 68.1 ± 5.0 for WAS + vehicle, $p < 0.05$, 92.3
208 ± 7.0 for WAS + ketotifen vs. WAS + vehicle, $p < 0.05$, Fig.4) .

209

210 ***IL-1 receptor antagonist, anakinra reversed repeated WAS-induced visceral***
211 ***allodynia.*** The administration of anakinra at 20 mg/kg twice before measuring the

212 threshold blocked the allodynia, but the antagonist did not change the threshold in sham
213 stress group (effect of WAS: $F = 14.4$, $p < 0.05$, effect of anakinra: $F = 11.2$, $p < 0.05$,
214 interaction of WAS and anakinra: $F = 6.0$, $p < 0.05$, 95.7 ± 2.9 for sham + vehicle vs.
215 66.3 ± 4.5 for WAS + vehicle, $p < 0.05$, 93.6 ± 5.5 for WAS + anakinra vs. WAS +
216 vehicle, $p < 0.05$, Fig.5).

217

218 ***IL-6 antibody blocked repeated WAS-induced visceral allodynia.*** IL-6 antibody at 16.6
219 $\mu\text{g}/\text{kg}$ injected twice before measuring the threshold also abolished the response by
220 repeated WAS without affecting the threshold in sham stress group (effect of WAS: $F =$
221 5.3 , $p < 0.05$, effect of IL-6 antibody: $F = 5.8$, $p < 0.05$, interaction of WAS and IL-6
222 antibody: $F = 17.0$, $p < 0.05$, 107.1 ± 7.4 for sham + vehicle vs. 70.0 ± 3.8 for WAS +
223 vehicle, $p < 0.05$, 107.8 ± 7.2 for WAS + IL-6 antibody vs. WAS + vehicle, $p < 0.05$,
224 Fig.6).

225

226 **Discussion**

227 There are several studies investigating the effects of repeated WAS on visceral
228 sensation in rodents, and the majority of them demonstrated that repeated WAS induced
229 visceral hypersensitivity.⁷⁻¹⁰ However, a few studies reported that it induced
230 hyposensitivity or no change.^{24, 25} The discrepancy of the results may be explained by
231 the difference of animals, sex or method measuring abdominal contractions induced by
232 colonic distention, such as EMG and noninvasive manometry.^{24, 26}

233 Our method detected the threshold of VMR by EMG with acute preparation, and
234 we showed previously that acute single WAS induced visceral hyposensitivity using this

235 method.²⁷ In the current study, we showed that 3-day WAS induced visceral allodynia,
236 and tried to determine the roles of peripheral CRF, mast cells, IL-1 and IL-6, which
237 were previously proved to mediate LPS-induced visceral allodynia.¹⁴

238 Several studies showed that acute WAS activates both central and peripheral
239 CRF signaling, which mediates altered GI motility and visceral sensation induced by
240 WAS.^{13, 27, 28} However, there were only few studies reporting the role of CRF signaling
241 on chronic WAS-induced visceral hypersensitivity. Larauche et al.¹⁰ showed that
242 repeated WAS-induced visceral hyperalgesia was prevented by repeated peripheral
243 injections of astressin before daily WAS session in rats. In the present study, the same
244 result was obtained, which further suggests that the development of visceral
245 hypersensitivity by chronic WAS may be mediated through peripheral CRF receptors,
246 because astressin is peripherally restricted CRF receptor antagonist.

247 Incidentally, the current study also demonstrated the interesting result that the
248 administration of astressin after 3-day WAS did not reverse the response by WAS. It
249 implies that activating peripheral CRF signaling may be an essential trigger for the
250 development of allodynia, but once established the hypersensitivity, it no longer may
251 contribute to the response.

252 Activating peripheral CRF/CRF₁ induces visceral hyperalgesia²⁹ and acute
253 stress such as CRD-induced visceral hyperalgesia was abolished by the peripheral
254 administration of astressin.²³ On the other hand, we previously demonstrated that
255 peripheral activation of CRF₁ did not induce visceral allodynia in the similar
256 experimental settings to the current study.¹⁴ Together with the results that astressin
257 prevented but did not reverse the allodynia, these lines of evidence suggest that

258 peripheral CRF/CRF₁ may directly contribute to the visceral hypersensitivity induced
259 by acute stress as opposed to chronic repeated WAS. Therefore we hypothesized that
260 peripheral CRF signaling activated by repeated WAS triggers to activate other systems,
261 thereby inducing visceral allodynia, but does not directly contribute to the response.

262 Mast cells have CRF receptors at their surface³⁰ and acute stress evokes mast
263 cells degranulation to release a large variety of mediators such as serotonin,
264 prostaglandins, etc., which is triggered by peripheral CRF in GI tract.³¹ These mediators
265 were demonstrated to activate visceral afferents,³² leading to induction of visceral
266 sensitization.²⁸ Additionally, chronic WAS is also known to increase and activate mast
267 cells,^{7, 18} and mast cells degranulation directly contributes to WAS-induced visceral
268 hypersensitivity in maternally separated rats.³³ The result of that ketotifen abolished the
269 allodynia by WAS in the present study is consistent with the evidence above. In
270 addition, we also confirmed that ketotifen abolished LPS-induced allodynia (data were
271 not shown), indicating that activation of mast cells may be one of the common pathways
272 mediating visceral hypersensitivity by chronic WAS and LPS.

273 Chronic WAS is well demonstrated to increase pro-inflammatory cytokines in
274 both gene and protein level in GI tract.^{7, 8, 34} However, it has not been shown that these
275 cytokines are directly involved in WAS-induced visceral hypersensitivity so far. We
276 believed that this is the first report showing the direct link between the cytokines and
277 chronic WAS-induced visceral hypersensitivity, since anakinra or IL-6 antibody
278 abolished the response.

279 IL-1 receptors are proved to be located in the neurons in rat dorsal root ganglia
280 (DRG).³⁵ IL-6-receptor complex binds to the transmembrane signal-transducing subunit,

281 glycoprotein 130, which is also expressed in DRG neurons.³⁶ Thus these cytokines
282 possibly evoke visceral hypersensitivity through directly activating sensory afferents
283 through these receptors.

284 The link between peripheral CRF and the pro-inflammatory cytokines on
285 modulating visceral sensation has been also suggested. Repeated WAS increases gut
286 permeability through peripheral CRF receptors and exogenous CRF administration
287 mimics this response.³⁷ Increased permeability leads to an increase in bacterial
288 translocation resulting in activating local immune system and inflammation, thereby
289 increasing the release of LPS and the cytokines.³⁸ CRF potentiates the response of
290 macrophages to LPS, i.e. enhancing the synthesis of the pro-inflammatory cytokines
291 through CRF₁.³⁹ Additionally, we have very recently shown that IL-1 β -induced
292 allodynia was not blocked by ip astressin,¹⁴ suggesting that IL-1 system may be more
293 downstream signaling to modulate the visceral sensation as compared to CRF on WAS-
294 induced allodynia. In this context, in addition to mast cells, these cytokines pathways
295 might also be one of the systems which CRF signaling modulates to develop visceral
296 allodynia. These scenarios may also explain the similarity of the pathways mediating the
297 visceral sensory response by chronic WAS and LPS.

298 We did not demonstrate the direct link between CRF and the cytokines. Besides,
299 various cells other than macrophage or monocyte, such as fibroblasts, endothelial,
300 neuronal, smooth muscle cells, etc.,^{40, 41} secrete our tested cytokines, but the sources
301 responsible for the allodynia were not determined. These are the limitations of our
302 study. Since other cytokines such as TNF- α , IL-8, etc., have been suggested to be
303 associated with the pathogenesis of IBS,⁴² the role of these cytokines should be also
304 evaluated in the future.

305 Growing evidence supports that peripheral immune mechanisms could
306 contribute to the IBS pathophysiology.^{42, 43} Some IBS patients exhibit low-grade gut
307 mucosal inflammation with activated mast cells and enhanced expression of pro-
308 inflammatory cytokines with increased serum LPS, resulting in abnormal neural
309 responses, leading to altered colonic functions.^{3, 15, 44} In this context, we previously
310 proposed that LPS-induced visceral allodynia is rat model of IBS.¹⁴ Present study
311 definitely showed that WAS activated mast cells, pro-inflammatory cytokines and
312 peripheral CRF systems, which contributed to chronic psychological stress-induced
313 visceral hypersensitivity. These systems are common pathways inducing visceral
314 allodynia by LPS and WAS, speculating that the link between brain and immune system
315 via peripheral CRF may play a crucial role in the pathophysiology of IBS.

316 In summary, we demonstrated that repeated WAS for 3 consecutive days
317 induced visceral allodynia which was mediated through mast cells, IL-1 and IL-6
318 pathways. Inhibition of peripheral CRF signaling prevented but did not reverse this
319 response, suggesting that peripheral CRF may be an essential trigger but may not
320 contribute to the maintenance of repeated WAS-induced visceral allodynia. These
321 results further suggest the crucial contribution of CRF, mast cells and cytokines systems
322 to the pathophysiology of IBS.

323

324

325 **References**

326

- 327 1 Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, *et al.* Bowel
328 disorders. *Gastroenterology*. 2016; **150**: 1393-1407.
- 329 2 Fukudo S, Suzuki J. Colonic motility, autonomic function, and gastrointestinal
330 hormones under psychological stress on irritable bowel syndrome. *Tohoku J Exp*
331 *Med*. 1987; **151**: 373-385.
- 332 3 Taché Y, Kiank C, Stengel A. A role for corticotropin-releasing factor in functional
333 gastrointestinal disorders. *Curr Gastroenterol Rep*. 2009; **11**: 270-277.
- 334 4 Nozu T, Okumura T. Corticotropin-releasing factor receptor type 1 and type 2
335 interaction in irritable bowel syndrome. *J Gastroenterol*. 2015; **50**: 819-830.
- 336 5 Hillhouse EW, Grammatopoulos DK. The molecular mechanisms underlying the
337 regulation of the biological activity of corticotropin-releasing hormone receptors:
338 implications for physiology and pathophysiology. *Endocr Rev*. 2006; **27**: 260-286.
- 339 6 Nozu T, Martínez V, Rivier J, Taché Y. Peripheral urocortin delays gastric
340 emptying: role of CRF receptor 2. *Am J Physiol Gastrointest Liver Physiol*. 1999;
341 **276**: G867-874.
- 342 7 Bradesi S, Schwetz I, Ennes HS, Lamy CM, Ohning G, Fanselow M, *et al.*
343 Repeated exposure to water avoidance stress in rats: a new model for sustained
344 visceral hyperalgesia. *Am J Physiol Gastrointest Liver Physiol*. 2005; **289**: G42-53.
- 345 8 Xu D, Gao J, Gilliland M 3rd, Wu X, Song I, Kao JY, *et al.* Rifaximin alters
346 intestinal bacteria and prevents stress-induced gut inflammation and visceral
347 hyperalgesia in rats. *Gastroenterology*. 2014; **146**: 484-496 e484.

- 348 9 Bradesi S, Martínez V, Lao L, Larsson H, Mayer EA. Involvement of vasopressin 3
349 receptors in chronic psychological stress-induced visceral hyperalgesia in rats. *Am*
350 *J Physiol Gastrointest Liver Physiol.* 2009; **296**: G302-309.
- 351 10 Larauche M, Bradesi S, Million M, McLean P, Taché Y, Mayer EA, *et al.*
352 Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia
353 induced by repeated psychological stress in rats. *Am J Physiol Gastrointest Liver*
354 *Physiol.* 2008; **294**: G1033-1040.
- 355 11 Chang L. The role of stress on physiologic responses and clinical symptoms in
356 irritable bowel syndrome. *Gastroenterology.* 2011; **140**: 761-765.
- 357 12 Larauche M, Mulak A, Taché Y. Stress and visceral pain: from animal models to
358 clinical therapies. *Exp Neurol.* 2012; **233**: 49-67.
- 359 13 Taché Y, Perdue MH. Role of peripheral CRF signalling pathways in stress-related
360 alterations of gut motility and mucosal function. *Neurogastroenterol Motil.* 2004;
361 **16 Suppl 1**: 137-142.
- 362 14 Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T. Lipopolysaccharide
363 induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral
364 corticotropin-releasing factor in rats. *J Gastroenterol.* 2017; **52**: 72-80.
- 365 15 Dlugosz A, Nowak P, D'Amato M, Mohammadian Kermani G, Nystrom J,
366 Abdurahman S, *et al.* Increased serum levels of lipopolysaccharide and anti-flagellin
367 antibodies in patients with diarrhea-predominant irritable bowel syndrome.
368 *Neurogastroenterol Motil.* 2015; **27**: 1747-1754.
- 369 16 Ortiz-Lucas M, Saz-Peiro P, Sebastian-Domingo JJ. Irritable bowel syndrome
370 immune hypothesis. Part two: the role of cytokines. *Rev Esp Enferm Dig.* 2010;
371 **102**: 711-717.

- 372 17 Liebrechts T, Adam B, Bredack C, Roth A, Heinzl S, Lester S, *et al.* Immune
373 activation in patients with irritable bowel syndrome. *Gastroenterology*. 2007; **132**:
374 913-920.
- 375 18 Soderholm JD, Yang PC, Ceponis P, Vohra A, Riddell R, Sherman PM, *et al.*
376 Chronic stress induces mast cell-dependent bacterial adherence and initiates
377 mucosal inflammation in rat intestine. *Gastroenterology*. 2002; **123**: 1099-1108.
- 378 19 Nozu T, Kumei S, Miyagishi S, Takakusaki K, Okumura T. Colorectal distention
379 induces acute and delayed visceral hypersensitivity: role of peripheral
380 corticotropin-releasing factor and interleukin-1 in rats. *J Gastroenterol*. 2015; **50**:
381 1153-1161.
- 382 20 Ness TJ, Gebhart GF. Colorectal distension as a noxious visceral stimulus:
383 physiologic and pharmacologic characterization of pseudoaffective reflexes in the
384 rat. *Brain Res*. 1988; **450**: 153-169.
- 385 21 Tang QL, Lai ML, Zhong YF, Wang AM, Su JK, Zhang MQ. Antinociceptive
386 effect of berberine on visceral hypersensitivity in rats. *World J Gastroenterol*.
387 2013; **19**: 4582-4589.
- 388 22 Martínez V, Rivier J, Wang L, Taché Y. Central injection of a new corticotropin-
389 releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related
390 alterations of gastric and colonic motor function. *J Pharmacol Exp Ther*. 1997;
391 **280**: 754-760.
- 392 23 Nozu T, Takakusaki K, Okumura T. A balance theory of peripheral corticotropin-
393 releasing factor receptor type 1 and type 2 signaling to induce colonic contractions
394 and visceral hyperalgesia in rats. *Endocrinology*. 2014; **155**: 4655-4664.

- 395 24 Larauche M, Gourcerol G, Million M, Adelson DW, Taché Y. Repeated
396 psychological stress-induced alterations of visceral sensitivity and colonic motor
397 functions in mice: influence of surgery and postoperative single housing on
398 visceromotor responses. *Stress*. 2010; **13**: 343-354.
- 399 25 Lee JY, Kim N, Kim YS, Nam RH, Ham MH, Lee HS, *et al*. Repeated Water
400 Avoidance Stress Alters Mucosal Mast Cell Counts, Interleukin-1beta Levels with
401 Sex Differences in the Distal Colon of Wistar Rats. *J Neurogastroenterol Motil*.
402 2016; **22**: 694-704.
- 403 26 Larauche M, Mulak A, Kim YS, Labus J, Million M, Taché Y. Visceral analgesia
404 induced by acute and repeated water avoidance stress in rats: sex difference in
405 opioid involvement. *Neurogastroenterol Motil*. 2012; **24**: 1031-e1547.
- 406 27 Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T. Water avoidance stress
407 induces visceral hyposensitivity through peripheral corticotropin releasing factor
408 receptor type 2 and central dopamine D2 receptor in rats. *Neurogastroenterol*
409 *Motil*. 2016; **28**: 522-531.
- 410 28 Gué M, Del Rio-Lacheze C, Eutamene H, Theodorou V, Fioramonti J, Bueno L.
411 Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and
412 mast cells. *Neurogastroenterol Motil*. 1997; **9**: 271-279.
- 413 29 Larauche M, Gourcerol G, Wang L, Pambukchian K, Brunnhuber S, Adelson DW,
414 *et al*. Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function
415 and visceral hypersensitivity in rodents primarily through peripheral pathways. *Am*
416 *J Physiol Gastrointest Liver Physiol*. 2009; **297**: G215-227.

- 417 30 Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast
418 cells as targets of corticotropin-releasing factor and related peptides. *Trends*
419 *Pharmacol Sci.* 2004; **25**: 563-568.
- 420 31 Overman EL, Rivier JE, Moeser AJ. CRF induces intestinal epithelial barrier injury
421 via the release of mast cell proteases and TNF-alpha. *PLoS One.* 2012; **7**: e39935.
- 422 32 Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, *et al.*
423 Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable
424 bowel syndrome. *Gastroenterology.* 2007; **132**: 26-37.
- 425 33 van den Wijngaard RM, Stanisor OI, van Diest SA, Welting O, Wouters MM,
426 Cailotto C, *et al.* Susceptibility to stress induced visceral hypersensitivity in
427 maternally separated rats is transferred across generations. *Neurogastroenterol*
428 *Motil.* 2013; **25**: e780-790.
- 429 34 Shi HL, Liu CH, Ding LL, Zheng Y, Fei XY, Lu L, *et al.* Alterations in serotonin,
430 transient receptor potential channels and protease-activated receptors in rats with
431 irritable bowel syndrome attenuated by Shugan decoction. *World J Gastroenterol.*
432 2015; **21**: 4852-4863.
- 433 35 Obreja O, Rathee PK, Lips KS, Distler C, Kress M. IL-1 beta potentiates heat-
434 activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase,
435 and protein kinase C. *FASEB J.* 2002; **16**: 1497-1503.
- 436 36 von Banchet GS, Kiehl M, Schaible HG. Acute and long-term effects of IL-6 on
437 cultured dorsal root ganglion neurones from adult rat. *J Neurochem.* 2005; **94**: 238-
438 248.
- 439 37 Sun Y, Zhang M, Chen CC, Gilliland M 3rd, Sun X, El-Zaatari M, *et al.* Stress-
440 induced corticotropin-releasing hormone-mediated NLRP6 inflammasome

- 441 inhibition and transmissible enteritis in mice. *Gastroenterology*. 2013; **144**: 1478-
442 1487, 1487.e1471-1478.
- 443 38 Yarandi SS, Peterson DA, Treisman GJ, Moran TH, Pasricha PJ. Modulatory
444 Effects of Gut Microbiota on the Central Nervous System: How Gut Could Play a
445 Role in Neuropsychiatric Health and Diseases. *J Neurogastroenterol Motil*. 2016;
446 **22**: 201-212.
- 447 39 Agelaki S, Tsatsanis C, Gravanis A, Margioris AN. Corticotropin-releasing
448 hormone augments proinflammatory cytokine production from macrophages in
449 vitro and in lipopolysaccharide-induced endotoxin shock in mice. *Infect Immun*.
450 2002; **70**: 6068-6074.
- 451 40 Zhang JM, An J. Cytokines, inflammation, and pain. *Int Anesthesiol Clin*. 2007; **45**:
452 27-37.
- 453 41 Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory
454 pathways. *Physiol Rev*. 2006; **86**: 515-581.
- 455 42 Elsenbruch S. Abdominal pain in irritable bowel syndrome: a review of putative
456 psychological, neural and neuro-immune mechanisms. *Brain Behav Immun*. 2011;
457 **25**: 386-394.
- 458 43 Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade
459 inflammatory bowel disease? *Gastroenterol Clin North Am*. 2005; **34**: 235-245.
- 460 44 Barbara G, Zecchi L, Barbaro R, Cremon C, Bellacosa L, Marcellini M, *et al*.
461 Mucosal permeability and immune activation as potential therapeutic targets of
462 probiotics in irritable bowel syndrome. *J Clin Gastroenterol*. 2012; **46 Suppl**: S52-
463 55.
- 464

465 **Figure legends**

466

467 **Figure 1**

468 **A** The threshold of visceromotor response (VMR) was determined by the
469 distended balloon volume (mL) inducing apparent sustained abdominal muscle
470 contractions. Demonstrable EMG recording was depicted. The threshold of VMR was
471 0.4 mL in this rat. **B** Schematic representation of experimental protocol. The surgery for
472 EMG electrodes and balloon placement were performed and 30 min later, basal VMR
473 threshold was measured. Then the animals were submitted to 1-hr stress session such as
474 water avoidance or sham stress. First, in order to establish the rat model of visceral
475 hypersensitivity, different times of daily stress session were loaded to each group of
476 animals until detecting significant visceral allodynia after repeated WAS. After 24 hr
477 from the last stress session, the animals underwent surgery again and the threshold was
478 determined. **C** Next, the mechanisms of repeated WAS-induced visceral
479 hypersensitivity was explored using this established model. Pharmacological
480 intervention was performed at 30 min and 15 hr before measurement of the threshold. **D**
481 In another series of experiment, stressin was administered at 10 min before each stress
482 session, repeatedly.

483

484 **Figure 2**

485 **A** Effect of repeated water avoidance stress (WAS) on the threshold of
486 visceromotor response (VMR) induced by colonic distention. 1- or 2-day WAS did not
487 alter the threshold, but 3-day WAS significantly reduced it. Sham stress did not modify

488 the threshold. * $p < 0.05$ vs. basal threshold by paired t test. **B** % change threshold was
489 significantly reduced in 3-day WAS group as compared with sham stress group. There
490 was no significant difference between 1 or 2-day WAS and respective control group. * p
491 < 0.05 vs. Sham by Student's t test. Each column represents the mean \pm SE. Number of
492 rats examined is shown in the parenthesis. Sham, sham stress.

493

494 Figure 3

495 The effect of astressin on repeated water avoidance stress (WAS)-induced
496 visceral allodynia. **A** Astressin (50 $\mu\text{g}/\text{kg}$) injected 10 min before each stress session
497 prevented WAS-induced allodynia without altering the threshold in sham-stressed rats.
498 * $p < 0.05$ vs. Vehicle + Sham, # $p < 0.05$ vs. Vehicle + WAS by two-way ANOVA
499 followed by Fisher's Least-Significant-Difference Test. **B** Astressin (200 $\mu\text{g}/\text{kg}$) injected
500 twice before the measurement of threshold after completing the 3-day stress session
501 neither modify the response induced by WAS nor the threshold in sham-stressed rats. *
502 $p < 0.05$ vs. Sham + Vehicle by two-way ANOVA followed by Fisher's Least-
503 Significant-Difference Test. Each column represents the mean \pm SE. Number of rats
504 examined is shown in the parenthesis. Sham, sham stress.

505

506 Figure 4

507 The effect of ketotifen on repeated water avoidance stress (WAS)-induced
508 visceral allodynia. Ketotifen at 3 mg/kg twice after completing the 3-day stress session
509 abolished the response induced by WAS without altering the threshold in sham-stressed
510 rats. * $p < 0.05$ vs. Sham + Vehicle, # $p < 0.05$ vs. WAS + Vehicle by two-way

511 ANOVA followed by Fisher's Least-Significant-Difference Test. Each column
512 represents the mean \pm SE. Number of rats examined is shown in the parenthesis. Sham,
513 sham stress.

514





515 Figure 5

516 The effect of anakinra on repeated water avoidance stress (WAS)-induced
517 visceral allodynia. Anakinra at 20 mg/kg twice before measuring the threshold after
518 stress sessions reversed WAS-induced allodynia without modifying the threshold in
519 sham-stressed rats. * $p < 0.05$ vs. Sham + Vehicle, # $p < 0.05$ vs. WAS + Vehicle by
520 two-way ANOVA followed by Fisher's Least-Significant-Difference Test. Each column
521 represents the mean \pm SE. Number of rats examined is shown in the parenthesis. Sham,
522 sham stress.

523

524 Figure 6

525 IL-6 antibody (ab) at 16.6 μ g/kg injected twice before measuring the threshold
526 blocked repeated water avoidance stress (WAS)-induced allodynia. However, IL-6 ab
527 per se did not alter the threshold. * $p < 0.05$ vs. Sham + Vehicle, # $p < 0.05$ vs. WAS +
528 Vehicle by two-way ANOVA followed by Fisher's Least-Significant-Difference Test.
529 Each column represents the mean \pm SE. Number of rats examined is shown in the
530 parenthesis. Sham, sham stress.



↓ = Surgery ∟ = Measurement ● = Water avoidance or sham stress
 ↑ = Astressin, ketotifen, anakinra, IL-6 antibody or vehicle injection
 ▲ = Astressin or vehicle injection

